Status: Recruiting
Sacituzumab Govitecan In TNBC
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Participants needed: 260
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Jun 2, 2026Locations: 5
Eligibility criteria
Female or male patients ≥ 18 years of age. [+13]
Inflammatory breast cancer, or locally recurrent breast cancer [+10]